Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)

Trial Profile

Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)

Phase of Trial: Phase I

Latest Information Update: 12 Nov 2014

At a glance

  • Drugs Trevogrumab (Primary)
  • Indications Muscular atrophy
  • Focus Pharmacodynamics
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 09 Nov 2014 Status changed from active, no longer recruiting to completed as reported by
    • 10 Jun 2014 Planned End Date changed from 1 Sep 2014 to 1 Oct 2014 as reported by record.
    • 10 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top